Search Results
Mar 26, 2026, 08:30 ET Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer
platform, now exceeding over half a million patients tested with Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS), H&E and IHC images with longitudinal follow-up clinical data. The novel Caris signatures for breast cancer and non-small cell lung cancer (NSCLC) predict a patient's
More news about: Caris Life Sciences
Mar 25, 2026, 08:30 ET Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026
leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), immunohistochemistry (IHC) and real world clinical data, to generate clinically meaningful insights across multiple tumor types. This research reflects Caris' commitment to advancing
More news about: Caris Life Sciences
Mar 24, 2026, 18:21 ET Discovery Life Sciences dan Mindpeak Bermitra Untuk Hadirkan Presisi AI Pada Tes Biomarker Kanker Dalam Uji Klinis Global
untuk mengatasi masalah tersebut secara langsung, dengan mengintegrasikan analisis citra digital berbasis AI ke layanan patologi untuk Imunohistokimia (IHC) dan Imunofluoresensi Multipleks (mIF) dalam uji klinis global.
More news about: Discovery Life Sciences
Mar 24, 2026, 12:27 ET Discovery Life Sciences 與 Mindpeak 宣佈合作，將人工智能的精準分析技術應用於全球臨床試驗的癌症生物標記檢測
Mindpeak 今日宣佈結成合作夥伴，旨在直接解決上述問題，將 AI 驅動的數碼影像分析應用於全球臨床試驗的免疫組織化學 (IHC) 及多重免疫螢光 (mIF) 病理學服務之中。
More news about: Discovery Life Sciences
Mar 24, 2026, 12:20 ET Discovery Life Sciences i Mindpeak nawiązują współpracę w celu wprowadzenia precyzyjnych rozwiązań opartych na sztucznej inteligencji do badań biomarkerów nowotworowych w globalnych badaniach klinicznych
zająć się tym problemem, wprowadzając analizę obrazów cyfrowych opartą na sztucznej inteligencji do usług patologicznych dotyczących immunohistochemii (IHC) i wielokrotnej immunofluorescencji (mIF) w globalnych badaniach klinicznych.
More news about: Discovery Life Sciences
Mar 24, 2026, 12:05 ET Partnerství společností Discovery Life Sciences a Mindpeak vnáší přesnost AI do testování biomarkerů rakoviny v globálních klinických studiích
partnerství, jehož cílem je přímo řešit tento problém a integrovat digitální analýzu obrazu s využitím AI do patologických služeb pro imunohistochemii (IHC) a multiplexní imunofluorescenci (mIF) v rámci globálních klinických studií.
More news about: Discovery Life Sciences
Mar 24, 2026, 12:02 ET Discovery Life Sciences e Mindpeak fazem parceria para levar precisão de IA aos testes de biomarcadores de câncer em ensaios clínicos globais
parceria destinada a enfrentar diretamente esse problema, integrando análise de imagens digitais com IA aos serviços de patologia para imunohistoquímica (IHC) e imunofluorescência multiplex (mIF) em ensaios clínicos globais.
More news about: Discovery Life Sciences
Mar 24, 2026, 11:10 ET Discovery Life Sciences et Mindpeak s'associent pour intégrer la précision de l'IA aux tests de biomarqueurs du cancer dans les essais cliniques mondiaux
répondre directement à ce problème, en intégrant l'analyse d'images numériques alimentée par l'IA dans les services de pathologie pour l'immunohistochimie (IHC) et l'immunofluorescence multiplex (mIF) dans les essais cliniques mondiaux.
More news about: Discovery Life Sciences
Mar 24, 2026, 11:07 ET Discovery Life Sciences và Mindpeak hợp tác để ứng dụng trí tuệ nhân tạo (AI) vào xét nghiệm dấu ấn sinh học ung thư trong các thử nghiệm lâm sàng tiến hành trên phạm vi toàn cầu
hợp tác nhằm giải quyết trực tiếp vấn đề nói trên, đưa phân tích hình ảnh kỹ thuật số được hỗ trợ bởi AI vào các dịch vụ bệnh lý về miễn dịch mô học (IHC) và miễn dịch huỳnh quang đa kênh (mIF) trong các thử nghiệm lâm sàng được tiến hành trên phạm vi toàn cầu.
More news about: Discovery Life Sciences
Mar 24, 2026, 08:00 ET Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
partnership designed to address that problem directly, integrating AI-enabled digital image analysis into pathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials.
More news about: Discovery Life Sciences
Mar 24, 2026, 08:00 ET Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
partnership designed to address that problem directly, integrating AI-enabled digital image analysis into pathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials.
More news about: Discovery Life Sciences
Mar 24, 2026, 08:00 ET Партнерство Discovery Life Sciences и Mindpeak привнесет точность ИИ в тестирование биомаркеров рака в глобальных клинических испытаниях
партнерстве, направленном на непосредственное решение этой проблемы, интегрируя цифровой анализ изображений с использованием ИИ в услуги по иммуногистохимии (IHC) и мультиплексной иммунофлуоресценции (mIF) в глобальных клинических испытаниях.
More news about: Discovery Life Sciences
Mar 24, 2026, 08:00 ET Discovery Life Sciences und Mindpeak kooperieren, um KI-Präzision für Krebs-Biomarker-Tests in globalen klinischen Studien zu ermöglichen
bekannt, die darauf abzielt, dieses Problem direkt anzugehen und die KI-gestützte digitale Bildanalyse in Pathologiedienstleistungen für Immunhistochemie (IHC) und Multiplex-Immunfluoreszenz (mIF) in globalen klinischen Studien zu integrieren.
More news about: Discovery Life Sciences
Mar 24, 2026, 08:00 ET Discovery Life Sciences spolupracuje s Mindpeak, aby zabezpečili presnosť testovania biomarkerov rakoviny pomocou umelej inteligencie v globálnych klinických skúšaniach
je priamo riešiť tento problém integráciou analýzy digitálneho obrazu s využitím umelej inteligencie do patologických služieb pre imunohistochémiu (IHC) a multiplexnú imunofluorescenciu (mIF) v globálnych klinických skúšaniach.
More news about: Discovery Life Sciences
Mar 24, 2026, 08:00 ET Discovery Life Sciences y Mindpeak se asocian en ensayos clínicos globales
abordar directamente este problema, integrando el análisis de imágenes digitales habilitado por IA en los servicios de patología para inmunohistoquímica (IHC) e inmunofluorescencia multiplex (mIF) en ensayos clínicos globales.
More news about: Discovery Life Sciences
Mar 24, 2026, 08:00 ET 디스커버리 라이프 사이언스와 마인드피크, 글로벌 임상시험 암 바이오마커 검사에 AI 정밀도 도입을 위한 파트너십 체결
변동성을 줄이고, 바이오마커 기반 임상시험의 위험을 낮추며, 중요한 개발 결정에 대한 신뢰를 강화함으로써 바이오 제약 연구개발 및 임상 연구를 지원하는 것을 목표로 한다.이번 파트너십은 마인드피크의 AI 플랫폼과 디스커버리의 조직 바이오마커 서비스를 결합해 IHC 및 mIF 슬라이드를 분석한다. 마인드피크의 기술은 병리학자 간 해석의 일관성을 개선해 바이오마커 개발의 위험을 줄이는 바이오 제약의 안전 도구로 기능한다. 여기에는 AI 기반 병리학 워크플로, 마인드피크의 피크아카데미(peakAcademy)를 통한 병리학자 교육,
More news about: Discovery Life Sciences
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
Fast Track Designation from the FDA for the treatment of adult patients with advanced/unresectable or metastatic HR-positive/HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy, CDK4/6 inhibitor, with or without chemotherapy for unresectable or metastatic
More news about: Duality Biotherapeutics, Inc.
Mar 24, 2026, 02:20 ET 映恩生物（9606.HK）公佈2025年度業績
EGFR 外顯子 19 缺失或 L858R 突變，且在接受第三代 EGFR 酪氨酸激酶抑制劑（TKI）及鉑類化療期間或之後出現疾病進展；2025 年 12 月，DB-1310 再獲 FDA 快速通道認定，適用於治療晚期 / 不可切除或轉移性 HR 陽性 / HER2 陰性（IHC 0、IHC 1 + 或 IHC 2+/ISH-）乳腺癌的成年患者，此類患者曾接受過內分泌治療、CDK4/6 抑制劑（無論是否聯合化療）用於治療不可切除或轉移性疾病，或在輔助化療期間或完成後 6 個月內出現疾病復發。深化全球合作，釋放戰略協同效應映恩生物持續推進映恩飛輪模式，深化全球合作，旨在實現自主研發資產價值的最大化。公司已構建起穩健的全球合作版圖，簽署的6項對外授權及共同開發協議總價值超過
More news about: Duality Biotherapeutics, Inc.
Mar 23, 2026, 09:16 ET Pictor Labs Introduces On-Prem Deployment for Virtual Stains at USCAP 2026
Stains, including ClearStain™, ReStain, and DeepStain™, enabling labs to generate high-fidelity virtual H&E, special stains, and immunohistochemistry (IHC) stains, locally and on demand. Virtual staining uses AI to generate digital pathology stains from standard brightfield images, enabling laboratories
More news about: PictorLabs
Mar 23, 2026, 08:52 ET Biocare Medical and Proteintech Announce Strategic Collaboration to Advance Next-Generation Antibody Technologies for Digital-Ready Pathology
and ROSEMONT, Ill., March 23, 2026 /PRNewswire/ -- Biocare Medical, a global leader in immunohistochemistry (IHC) reagents and diagnostic assay solutions, and Proteintech, a global leader in the development and manufacturing of antibodies and proteins for life science
More news about: Biocare Medical and Proteintech Group
Mar 19, 2026, 10:01 ET Preimplantation Genetic Testing Market to Reach US$ 1,081.9 Million by 2033 Amid Rising IVF Adoption and Technological Innovation - Persistence Market Research
Platforms, Software & Services), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Flow Cytometry, Immunohistochemistry (IHC), Others), Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Others), End-user, and Regional Analysis from 2026 – 2033
More news about: Persistence Market Research Pvt. Ltd.
Mar 18, 2026, 11:22 ET 總生存期顯著延長：蘆康沙妥珠單抗(sac-TMT) OptiTROP-Lung03研究OS最終分析結果亮相
LC；既往至少接受過2種系統治療（其中至少1種治療針對晚期或轉移性階段）的不可切除的局部晚期或轉移性TNBC；經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的HR+/HER2- (IHC 0、IHC 1+或IHC 2+/ISH-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲NMPA授予6項突破性療法認定(BTD)。蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2
More news about: 科倫博泰
Mar 18, 2026, 10:27 ET Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications listed above have
More news about: Kelun-Biotech
Mar 18, 2026, 08:34 ET Biocare Medical and PreciPoint Announce Co-Exclusive Distribution Partnership to Expand Access to Digital Pathology for IHC and ISH
compatible with Biocare IHC workflows and supportive of AI-enabled digital QC solutions. SAN FRANCISCO and MUNICH, March 18, 2026 /PRNewswire/ -- Biocare Medical, a provider of immunohistochemistry (IHC) and in situ hybridization
More news about: Biocare Medical and PreciPoint GmbH
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Pharmaceuticals. "Zanidatamab is already delivering meaningful benefits for adult patients with previously treated, unresectable or metastatic HER2+ (IHC 3+) biliary tract cancer. We are advancing our program in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma, and generating
More news about: Jazz Pharmaceuticals plc